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ARTICLE
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Jennifer A. Donald, Ron A. Wevers, John Christodoulou, and Hans van Bokhoven
Arts syndrome is an X-linked disorder characterized by mental retardation, early-onset hypotonia, ataxia, delayed motor
development, hearing impairment, and optic atrophy. Linkage analysis in a Dutch family and an Australian family
suggested that the candidate gene maps to Xq22.1-q24. Oligonucleotide microarray expression proﬁling of ﬁbroblasts
from two probands of the Dutch family revealed reduced expression levels of the phosphoribosyl pyrophosphate syn-
thetase 1 gene (PRPS1). Subsequent sequencing of PRPS1 led to the identiﬁcation of two different missense mutations,
c.455TrC (p.L152P) in the Dutch family and c.398ArC (p.Q133P) in the Australian family. Both mutations result in a
loss of phosphoribosyl pyrophosphate synthetase 1 activity, as was shown in silico by molecular modeling and was shown
in vitro by phosphoribosyl pyrophosphate synthetase activity assays in erythrocytes and ﬁbroblasts from patients. This
is in contrast to the gain-of-function mutations in PRPS1 that were identiﬁed previously in PRPS-related gout. The loss-
of-function mutations of PRPS1 likely result in impaired purine biosynthesis, which is supported by the undetectable
hypoxanthine in urine and the reduced uric acid levels in serum from patients. To replenish low levels of purines,
treatment with S-adenosylmethionine theoretically could have therapeutic efﬁcacy, and a clinical trial involving the two
affected Australian brothers is currently underway.
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Phosphoribosyl pyrophosphate synthetase 1 (PRS-I) is a
member of a family of phosphoribosyl pyrophosphate
(PRPP) synthetases that catalyze the synthesis of PRPP
from ATP and ribose-5-phosphate.1 PRPP is essential for
de novo purine and pyrimidine synthesis. In men, there
are three genes for the PRPP synthetase family—PRPS1
(MIM 31185), PRPS2 (MIM 311860), and PRPS1L1—all of
which encode nearly (190%) identical proteins. PRPS1 and
PRPS2 have multiple exons and map to the long and short
arms of the X chromosome, respectively. PRPS1L1 is an
intronless gene located on chromosome 7 that appears to
have arisen through retrotransposition of a spliced PRPS1
or PRPS2 transcript. The expression of PRPS1L1 is limited
to testis,2 whereas PRPS1 and PRPS2 are expressed in all
tissues.3
Previously described missense mutations in PRPS1 cause
PRPP synthetase superactivity, which results in PRPS-re-
lated gout (MIM 311850).1 In addition, overexpression of
PRPS1 causes the same syndrome, although the underly-
ing mechanism remains elusive.4 PRPS-related gout is
characterized by purine nucleotide and uric acid overpro-
duction,5–7 gout,6,8 and sometimes neurological problems,
most notably mental retardation, hypotonia, and senso-
rineural deafness.8–11 PRPS-related gout is 1 of the 14 dif-
ferent known disorders caused by inborn errors of purine
and pyrimidine metabolism.12 The accumulation of pu-
rines to toxic levels can result in a variety of clinical symp-
toms, such as renal stones, gouty arthritis, developmental
delay, hypotonia, and immunodeﬁciency. Susceptibility to
infections and developmental delay are also seen in dis-
orders of pyrimidine metabolism, such as orotic aciduria
(MIM 258900) and pyrimidine nucleotide depletion.12,13
Arts syndrome (MIM 301835) is deﬁned by mental re-
tardation, early-onset hypotonia, ataxia, delayed motor
development, hearing impairment, and optic atrophy.14
Susceptibility to infections, especially of the upper respi-
ratory tract, can result in an early death. Interestingly, Arts
syndrome shows characteristics in common with purine-
overproduction disorders, such as mental retardation, de-
layed motor development, ataxia, sensorineural impair-
ment, and recurrent infections, symptoms that occur in
patients with hypoxanthine guanine phosphoribosyl-
transferase (HPRT1) deﬁciency (MIM 300322), purine nu-
cleoside phosphorylase (PNP) deﬁciency (MIM 164050),
and PRPP synthetase superactivity.12 However, Arts syn-
drome lacks evidence of purine overproduction, since pa-
tients do not develop renal stones or gout (authors’ un-
published observations).
Here, we report that Arts syndrome is caused by mis-
sense mutations in PRPS1. In contrast to PRPS-related
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gout, the missense mutations in Arts syndrome cause a
loss of function, which was validated in silico bymolecular
modeling; in vitro by PRPP synthetase activity assays in
erythrocytes, Epstein-Barr virus–transformed lymphoblas-
toid cell lines (EBV-LCLs), and skin ﬁbroblasts from pa-
tients and carrier females; and in vivo by analysis of me-
tabolites in urine and plasma from patients and carrier
females. These results emphasize the importance of the
tight regulation of PRPP synthetase activity and that in-
creased or reduced activity can give rise to clinically dis-
tinct human disorders.
Material and Methods
Genetic Mapping of Australian Family F
DNA from family F was extracted from peripheral whole blood
by the salting-out method as described by Miller et al.15 Prelim-
inary X-chromosome mapping in family F was performed using
the ABI Prism set version 2, panel 28 (X chromosome), obtained
from Applied Biosystems. This set comprised primers for 18 ﬂuo-
rescently labeled microsatellite markers dispersed at intervals of
∼10 cM over the entire X chromosome. Markers for the ﬁne map-
ping of the candidate regions were spaced at 0.4–5 cM. The for-
ward primers for these microsatellites were ﬂuorescently labeled
with Fam, Hex, or Ned. PCR conditions were optimized for in-
dividual primers and are available on request.16 PCRs were per-
formed in a 9600 thermocycler (Applied Biosystems). The pro-
grams used were 95C for 12 min for one cycle, followed by 35
cycles of melting at 94C for 15 s, annealing at the optimal tem-
perature for 15 s, and then extension at 72C for 30 s. A ﬁnal
extension was performed at 72C for 4 min. PCR products were
run on an ABI 377 sequencer (Applied Biosystems). Exclusion
mapping was used to identify candidate regions on the X chro-
mosome under the following assumptions: alleles not shared be-
tween the two affected brothers were excluded, alleles shared
between the affected brothers and their unaffected maternal un-
cle were excluded, and alleles inherited from the maternal grand-
father were excluded.
Cell Culturing
Skin ﬁbroblast cell lines were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM [Gibco]) supplemented with 20% (v/v)
fetal calf serum (Sigma), 1% 10-U/ml penicillinwith 10-mg/ml strep-
tomycin (Gibco), 1% GlutaMAX (Gibco), and 1 mM sodium py-
ruvate (Gibco). Cells were harvested at 80%–90% conﬂuence for
both RNA isolation and PRPP synthetase activity analysis by
washing once with PBS buffer (8 mM Na2HPO4, 2 mM KH2PO4,
137 mM NaCl, and 2.7 mM KCl [pH 7.2]), followed by treatment
with 0.25% trypsin (Sigma) in PBS. Cells were centrifuged at 200
g for 5 min at room temperature, were washed with PBS, andwere
pelleted by centrifugation at 200 g for 5min at room temperature.
This last step was repeated for PRPP synthetase activity analysis.
Pellets for both RNA isolation and enzyme activity analysis were
immediately snap frozen in liquid nitrogen.
Human B-lymphocytes were immortalized by transformation
with Epstein-Barr virus in accordance with established procedu-
res.17 EBV-LCLs from patients and controls were grown to a den-
sity of 0.7 million cells per ml RPMI 1640 medium (Gibco) con-
taining 10% (v/v) fetal calf serum (Sigma), 1% 10-U/ml penicillin
and 10-mg/ml streptomycin (Gibco), and 1% GlutaMAX (Gibco).
A total of 25 million cells were harvested by centrifugation at 200
g for 5 min at room temperature, were washed with PBS, andwere
pelleted by centrifugation at 200 g for 5min at room temperature.
The pellets for enzyme activity analysis were immediately snap
frozen in liquid nitrogen.
RNA Isolation
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) in
accordance with the manufacturer’s protocol. To remove residual
traces of genomic DNA, the RNA was treated with DNase I (In-
vitrogen) while bound to the RNeasy column. The integrity of
the RNA was assessed on an agarose gel, and the concentration
and purity were determined by optical densitometry. Poly-ARNA
was isolated using the Oligotex Direct mRNA Kit (Qiagen) in ac-
cordance with the manufacturer’s protocol.
Expression Proﬁling
Total RNA from eight healthy control males and females was
divided into two reference pools consisting of four different sam-
ples. These served as references to establish differential gene ex-
pression in ﬁbroblast cell lines of the two affected members of
family N032. GeneChip expression analysis using the GeneChip
Human Genome U133 Plus 2.0 Array was performed in accor-
dance with the manufacturer’s protocol (Affymetrix) by use of
total RNA and the one-cycle target-labeling assay. Data from both
affected family members were averaged and were compared with
the combined reference data by use of Genespring (Agilent Tech-
nologies). Probe sets that had a signal value !100 were regarded
as “not expressed.” In addition, probe sets with probes in intronic
sequences that were not supported by human mRNAs from
GenBank or by spliced ESTs were not considered. If a probe set
was reduced in expression, the probes in that particular set were
checked for redundancy and were discarded if more than half the
probes in the set could bind to more than one transcript. When
multiple probe sets were present for one transcript, at least two
had to be reduced in expression.
First-Strand Synthesis for Quantitative PCR (qPCR)
The poly-A RNA equivalent of 5 mg of total RNA was transcribed
into cDNA as follows. Poly-A RNA (0.2 mg total RNA/ml), 0.05 U/
ml pd(N)6 (Amersham Biosciences), and 1 mM deoxyribonucleo-
tide triphosphate (dNTP) (Invitrogen) were incubated for 5 min
at 65C. The mixture was then cooled on ice for 1 min. First-
strand buffer (Invitrogen), 10 mM dithiothreitol, and 0.5 U/ml
RNA Guard (Amersham Biosciences) were added. One-tenth of
the reaction mixture served as the minus–reverse transcriptase
control. M-MLV reverse transcriptase (Invitrogen) was added for
a ﬁnal concentration of 10 U/ml. This solution was, in subsequent
steps, incubated at 25C for 10 min, at 50C for 50 min, and at
70C for 15 min. cDNA was puriﬁed using QIAquick columns
(Qiagen) in accordance with the manufacturer’s protocol.
qPCR
qPCR was performed by SYBR Green–based quantiﬁcation in ac-
cordance with the manufacturer’s protocol (BioRad) by use of an
iCycler (MyiQ single-color real-time detection System [BioRad]).
Primers were developed using the Primer3 program.18 In the case
of GUSB (MIM 253220) and CUL4B (MIM 300304), the primers
were designed on two separate exons. GUSB is stably expressed
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Table 1. Sequences of Primers Used for qPCR and Direct DNA Sequencing
Procedure and
Gene or Exon
GenBank
Accession
Number
Primer Sequence
(5′r3′)
Forward Reverse
qPCR:
PRPS1 NM_002764.2 gatctatttggcctctcaaa cacacaggtacacacactttatt
PRPS2 NM_002765.3 ggacctgcatgcttctcag atgttttcccgaatccactg
CUL4B NM_003588.3 accaccgtctctagctttgc tttgccaggtttcatctgtg
GUSB NM_000181.1 agagtggtgctgaggattgg ccctcatgctctagcgtgtc
Direct DNA sequencing:
CUL4B exon 1.1 NM_003588.3 cactaccctgatgcaccacc tgtatttaacaccttccggg
CUL4B exon 1.2 NM_003588.3 tcttttggctccaaccagg ccaggtccaccttcaataag
CUL4B exon 2 NM_003588.3 attggctgggaaaccagag cctgacctcgtgatctgctc
CUL4B exon 3.1 NM_003588.3 acgcacgcaggcatataaac caaaccctacaaactccaggg
CUL4B exon 3.2 NM_003588.3 cttcaacctcgtccttctgc gacccctcgagtgtcaaatc
CUL4B exon 4 NM_003588.3 ggtgagtcaaaatgacttaaacag cccatggtttatgtgagaatacg
CUL4B exon 5 NM_003588.3 tgtcttaagtggatgaataaccc gctgggttaaacagtgaggg
CUL4B exon 6 NM_003588.3 tatgctctctgtcacatggc gaagcaatctccctattgctaag
CUL4B exon 7 NM_003588.3 tagatgtgtttatctgcatgtttg caaaggaaagtctagaaccaaatg
CUL4B exon 8 NM_003588.3 aattagcatgggaacatgtgg cattacctgtctgatgtgggg
CUL4B exon 9 NM_003588.3 acaaaaggatcctagcttgatg gagaagagcatcacaatgttgg
CUL4B exon 10 NM_003588.3 ccacttccaggatcttttgg tgctgcaagtgatttaacgac
CUL4B exon 11 NM_003588.3 cccctcaggagaggctttac ttccctactagtttgccactacc
CUL4B exon 12 NM_003588.3 tacccagaaagatggttggg tcaaacaagaaatgcttgcc
CUL4B exon 13 NM_003588.3 tggggattgttttcattgtag cttgatataccagctaagcaacc
CUL4B exon 14 NM_003588.3 cccagtacctcgtgtattccc tccctccagtttgaatatacttg
CUL4B exon 15 NM_003588.3 agacttcgaaatgtctggcac gaggaaatcgattgaaaggg
CUL4B exon 16 NM_003588.3 tcgtgtttcccacttttaaacc gccatgaattacaacaaacacg
CUL4B exon 17 NM_003588.3 tttaaggatggtcagtgtttgc caatacagcgagaccctgg
CUL4B exon 18 NM_003588.3 tttgatttggtggttgggag gcggtgagccaagatagc
CUL4B exon 19 NM_003588.3 taccacgtcaagtggctttg caaaacagttctgaggcaagg
CUL4B exon 20 NM_003588.3 tggagtggaagctagattgagg aatggtattggcagtattacagg
CUL4B exon 21 NM_003588.3 caatgtcatgtccctaaaatgc tcatgacgctttatgtttgc
CUL4B exon 22 NM_003588.3 ggggtattaactaaatgggcttg tgcaaagagttcaacaacattc
PRPS1 exon 1 NM_002764.2 tgagtctgtggccgacttc cgaccccatccctcctatac
PRPS1 exon 2 NM_002764.2 tcaatccacacttggttgaatc tccagaggagttggtgcttag
PRPS1 exon 3 NM_002764.2 atgaatttctgggtaccatagtg cttctctgcagtcttcagcatc
PRPS1 exon 4 NM_002764.2 aatctaccacactgggcctg ccatgtgctagctacttacatcc
PRPS1 exon 5 NM_002764.2 ccccggcctctttagtcc tcagcaggctgaagacattc
PRPS1 exon 6 NM_002764.2 gttgtggaagcctaagcagg cttcagaatccagagacctaattc
PRPS1 exon 7.1 NM_002764.2 tcatgacagggaaacagcac gagcttccccagtcacagtc
PRPS1 exon 7.2 NM_002764.2 ttaactgctgggacctcctac gaagcatgtttgctttccag
in ﬁbroblasts and thus is a good reference gene to use.19 Since
PRPS1 and PRPS2 are very similar, primers had to be designed that
anneal to the 3′ UTR of these genes. Sequences of the qPCR prim-
ers are shown in table 1. PCR products were 80–120 bp in length.
All primer pairs were validated in triplicate by use of serial cDNA
dilutions that result in end concentrations equivalent to 800, 400,
200, 100, and 50 pg/ml of total RNA input into the ﬁrst-strand
synthesis. Primers that were efﬁcient, which implies100% 5%
a doubling of PCR product in each cycle, were used to quantify
mRNA levels. qPCR quantiﬁcations were performed with the
equivalent of 400 pg/ml of total RNA input into the ﬁrst-strand
synthesis from two separate ﬁrst-strand syntheses each in dupli-
cate, and they included a water or minus–reverse transcriptase
control. The quantiﬁcation was repeated on separately grown cell
lines, and the results were averaged. Experimental threshold cy-
cles (Ct) values were within the range of cDNA dilutions used to
validate the primers. The melting curves of all PCR products
showed a single PCR product. All controls were negative. Differ-
ences in the expression of a gene of interest between two samples
were calculated by the comparative Ct or 2DDCt method.20,21
Mutation Analysis
Primer sequences for ampliﬁcation of all exons of CUL4B
(GenBank accession number NM_003588.3) and PRPS1 (GenBank
accession number NM_002764.2) are shown in table 1. Of the
last exon of CUL4B and PRPS1, 210 nt and 750 nt of the 3′ UTR
were analyzed, respectively. PCR conditions are available on re-
quest. PCR products were sequenced using the ABI PRISM BigDye
Terminator Cycle Sequencing version 2.0 Ready Reaction Kit and
were analyzed using the ABI PRISM 3730 DNA analyzer (Applied
Biosystems). In the case of TRPC5 (GenBank accession number
NM_012471.2; MIM 300334), the entire coding region of the can-
didate gene was ampliﬁed using the methods of Sossey-Alaoui et
al.22 Automated ABI 377 sequencing was performed using both
forward and reverse primers from each PCR.
The segregation of the c.455TrC nucleotide change in PRPS1
in family N032 and its presence in 169 healthy males and 70
healthy females were tested by ampliﬁcation of exon 4 and sub-
sequent digestion by BsmFI in accordance with the manufac-
turer’s protocols (Invitrogen). The segregation of nucleotide sub-
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Table 2. General Clinical Description of the Two
Families with Arts Syndrome
Clinical Symptom
Family
N032
Family
F
PRPS1-
Related
Gout
Mental retardation   
Ataxia   
Hypotonia   
Delayed motor development   
Recurrent infections   
Hearing impairment   
Optic atrophy   
Areﬂexia   
Loss of deep tendon reﬂexes   
Gout   
Kidney stones   
Early death   
NOTE.—A positive sign () indicates the presence of the symptom;
a negative sign () indicates the absence of the symptom.
stitution c.398ArC in PRPS1 in family F and its presence in 154
healthy females were tested by ampliﬁcation of exon 3 and sub-
sequent digestion with ApoI in accordance with the manufac-
turer’s protocols (Invitrogen).
Molecular Modeling
The effect of the p.Q133P and p.L152Pmutations on the structure
of PRS-I was examined using the crystal structure of humanPRPS1
from Li et al.23 (RCSB Protein Data Bank entry 2H06). The altered
amino acid side chains in the model were positioned using a
backbone-dependent rotamer library as implemented in the
Yet Another Scientiﬁc Artiﬁcal Reality Application (YASARA) pro-
gram. The models were subsequently reﬁned using the Yamber2
force ﬁeld, which elsewhere was shown to increase model accu-
racy.24 Coordinate ﬁles are available from the authors on request.
PRPP Synthetase Activity Analysis
PRPP synthetase activity in erythrocytes is based on high-perfor-
mance liquid chromatography (HPLC) measurement of adeno-
sine monophosphate (AMP), which is produced from the enzyme
reaction in equimolar amounts with PRPP. The assay contains
diadenosine pentaphosphate (A2P5), which inhibits dephos-
phorylation of ATP and adenosine diphosphate (ADP) by non-
speciﬁc phosphatases. In brief, erythrocytes were washed in saline
and were stored frozen until required. For the assay, 100 ml of
packed erythrocytes were lysed by freeze thawing in 500 ml buffer
comprising 10 mM Tris-HCl (pH 7.5), 1 mM dithiothreitol, and
1 mM EDTA. Centrifuged lysate was dialyzed to remove eryth-
rocyte nucleotides, by passing through a Sephadex G-25 column
equilibrated with the lysis buffer mentioned above containing
0.9% (w/v) NaCl. The 150-ml assay mixture contained 50 mM
Tris-HCl, 0.5 mM ATP, 0.25 mM ribose-5-phosphate, 0.25 mM
A2P5, 1 mM dithiothreitol, 5 mM MgCl2, and inorganic phos-
phate that varied in concentration from 0 to 32 mM. Each assay
was commenced by the addition of 50 ml of dialyzed hemolysate
and was incubated for 20 min at 37C. The reaction was termi-
nated by the addition of trichloroacetic acid, and the supernatant
was subjected to ion-pair HPLC to separate the AMP.25
Frozen EBV-LCL and ﬁbroblast pellets were suspended in 300
ml 0.9% (w/v) NaCl and were sonicated three times at 4 W for 10
s, with intervals of 30 s under constant cooling in ice water. After
centrifugation (11,000 g at 4C for 20 min), 250 ml of the super-
natant was diluted with 250 ml 0.9% (w/v) NaCl and was con-
centrated on a Microcon YM-10 ﬁlter (Millipore) by centrifuga-
tion (14,000 g at 4C for 60 min). The protein fraction was diluted
to a ﬁnal volume of 500 ml, with 0.9% (w/v) NaCl, and was con-
centrated again by centrifugation. The ﬁnal concentrated protein
fraction was saved, and the protein concentration was deter-
mined with a copper-reduction method using bicinchonic acid,
essentially as described by Smith et al.26 The activity of PRPP
synthetases in EBV-LCLs was determined in a reaction mixture
containing an aliquot of cell sample (0.05–0.65 mg), 40 mM so-
dium phosphate, 1 mM dithiothreitol, 6 mM MgCl2, 1.54 mM
ATP, 100 mM ribose-5-phosphate, 50 mM P1,P5-di(adenosine-
5′)pentaphosphate (Ap5A), and 50 mM Tris/MOPS (pH 7.4). The
activity of PRPP synthetases in ﬁbroblasts was determined in a
reaction mixture containing an aliquot of cell sample (0.02–0.032
mg), 32 mM sodium phosphate, 1 mM dithiothreitol, 5 mM
MgCl2, 0.5 mM ATP, 150 mM ribose-5-phosphate, 250 mM Ap5A,
and 50 mM Tris/HCL (pH 7.4).27 Separation of AMP, ADP, and
ATP was performed isocratically (30% 0.0075-mM sodium phos-
phate to 70% 0.75-mM sodium phosphate [pH 4.55]) at a ﬂow
rate of 0.8 ml/min by HPLC on an ion-exchange column (What-
man Partisphere SAX mm; 5 mm particle size [VWR125# 4.6
International]) and a guard column (Whatman Partisphere AX
mm; 5 mm particle size [VWR International]) with online10# 2.5
UV detection at 254 nm.
Metabolite Analysis in Urine
Urine and plasma purines and pyrimidines were determined us-
ing reversed-phase HPLC analysis as described elsewhere,28 with
the modiﬁcation that a mm (3m) Synergi RP80A C18250# 3.1
column (Phenomenex) was used. Purine and pyrimidine metab-
olites were identiﬁed by their retention times and spectra (230–
330 nm) by photodiode array detection.
Results
Clinical Description
In this article, two families with Arts syndrome were in-
vestigated. Family N032 is the original Dutch family de-
scribed extensively by Arts et al.14 In short, the syndrome
is deﬁned by mental retardation, early-onset hypotonia,
ataxia, delayed motor development, hearing impairment,
and optic atrophy (table 2). Susceptibility to infections,
in particular of the upper respiratory tract, resulted in an
early death, before age 5 years, for 9 of the 10 affected
males in this family. Only one patient lived beyond age
5 years, reaching age 18 years. The CNS of one patient
was examined at autopsy. In the posterior columns of the
spinal cord, an almost complete absence of myelin was
found. Carrier females from family N032 show isolated
and milder manifestations of symptoms of Arts syndrome,
such as perceptive hearing impairment, ataxia, hypotonia,
and hyperreﬂexia.
The Australian family (family F) was ascertained inde-
pendently (for pedigree, see ﬁg. 1A). The two affected
boys, III-2 and III-3, have mental retardation, hypotonia,
ataxia, profound congenital sensorineural deafness, pro-
gressive peripheral neuropathy, and optic atrophy. They
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Figure 1. Pedigree of family F (A) and the overlapping linkage
intervals between family F (B) and family N032 (C). Indicated are
the positions of the genes analyzed in patients as described in
this article (bold font) and as previously described by de Brouwer
et al.29
also displayed slowly progressive muscle weakness asso-
ciated with intermittent acute deterioration in muscle
strength during intercurrent illnesses. The acute episodes
of muscle weakness resulted in respiratory failure, requir-
ing mechanical ventilation for a period of time. Both boys
had delayed motor-nerve conduction velocities and an
electromyogram suggestive of denervation, which is con-
sistent with the clinical ﬁndings that suggested peripheral
neuropathy. In addition, the younger boy had a ﬁbrosing
pancreatitis, the cause of which was never established. A
sural nerve biopsy in the older boy revealed mild para-
nodal demyelination. Other investigations with normal
ﬁndings included urine amino and organic acid screens,
blood lactate, liver-function tests, karyotype, magnetic
resonance imaging of the brain, screening for the c.35delG
mutation in GJB2 (MIM 121011), and, in the older boy,
muscle and liver respiratory-chain enzyme studies and
testing for several of the common mtDNA point muta-
tions. The affected boys are currently aged 11 and 9 years.
Their sister, III-1, is currently aged 13 years, is completely
asymptomatic, and has normal hearing. Their parents
are both healthy, and the mother has normal hearing,
whereas the father has mild adult-onset hearing impair-
ment. One of the maternal uncles, II-1, was thought to
have Duchenne muscular dystrophy and died at age 2
years. He never learned to speak, and, in retrospect, it is
likely that he, too, had Arts syndrome. Another maternal
uncle, II-2, currently aged 27 years, had hydrocephalus of
uncertain etiology, which required shunting in infancy.
The thirdmaternal uncle, II-3, died of sudden infant death
syndrome at age 6 mo.
Linkage Analysis
The genetic defect in both families was linked to the X
chromosome. In family N032, the 21-Mb linkage interval
was previously described by Kremer et al.30 and is ﬂanked
by the polymorphic markersDXS1231 andDXS1001,with
a maximum LOD score of 6.97 (ﬁg. 1C). The interval con-
tains 227 annotated genes (NCBI Map Viewer build 36.2).
Mutations in known X-linked mental retardation genes
ACSL4 (MIM 300157), AGTR2 (MIM 300034), PAK3 (MIM
300142), and UBE2A (MIM 312180) were excluded by di-
rect DNA sequencing.29 Copy-number variations 1200 kb
were excluded as well by use of array comparative genomic
hybridization on a full-coverage X-chromosome BAC
array.31
For family F, an exclusion-mapping approachwas taken,
because a recessive X-linked defect was suspected and the
family was too small to reach a signiﬁcant LOD score. The
uncle with hydrocephalus, II-2, was presumed to have an
unrelated disorder (i.e., was considered unaffected for the
purposes of this study), and themother, II-4, andmaternal
grandmother, I-2, were presumed to be carriers for the
disorder. Therefore, alleles not inherited from the mater-
nal grandmother were excluded, as were alleles shared
with the unaffected uncle II-2. In this way, three candidate
regions were identiﬁed in this family, one of ∼13 cM at
Xq23 between markers DXS1106 and DXS8064, which
overlaps with the linkage interval of family N032 (ﬁg.
1B), one ∼3-cM region at Xq27 between DXS1227 and
DXS8043 and one ∼8-cM region at Xq27 between
DXS8043 and DXS8091. The transient receptor potential
channel 5 gene (TRPC5), which is located within theXq23
candidate region identiﬁed in family F, was chosen as an
initial candidate gene. TRPC5 is expressed exclusively in
the adult and developing CNS, and it has proposed that
it forms receptor-mediated nonselective cation channels
in CNS cells.22,32–34 It is thus a candidate for mental retar-
dation and other developmental disorders, such as Arts
syndrome.22 One change, c.919-42ArG, was identiﬁed in
the affected boys in family F and in their normal father
and maternal grandfather. It is therefore likely to be a
common polymorphism.
Expression Proﬁling in Family N032
Fibroblast cell lines from two affected members of family
N032, IV-2 and V-5 (for patient designation, see the work
of Arts et al.14), were analyzed by expression proﬁling with
the use of the GeneChip Human Genome U133 Plus 2.0
Array. The combined expression proﬁle of the two affected
family members was compared with the combined ex-
pression proﬁle of two pools of four separate cell lines from
healthy control individuals (see the tab-delimited ASCII
ﬁle [online only], which can be imported into a spread-
sheet). The three genes that were most reduced in ex-
pression in the linkage interval were CUL4B, C1GALT1C1
(MIM 300611), and PRPS1 (table 3); they were reduced in
expression 1.9-fold, 1.4-fold, and 1.4-fold, respectively.
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Table 3. Top 10 Probe Sets with the Most Reduced Expression
in the Linkage Interval on the X Chromosome in Family N032
Probe Set Gene
Accession Number
Expression
Level
log2
Ratio
Fold
ReductionGenBank MIM
210257_x_at CUL4B AF212995 300304 321 .91 1.9
215997_s_at CUL4B AV694732 300304 277 .81 1.8
219283_at C1GALT1C1 NM_014158 300611 905 .50 1.4
208447_s_at PRPS1 NM_002764 311850 1,925 .46 1.4
205584_at CXorf45 NM_024810 … 122 .39 1.3
201215_at PLS3 NM_005032 300131 1,753 .37 1.3
219771_at TBC1D8B NM_017752 … 223 .37 1.3
202371_at TCEAL4 NM_024863 … 1,273 .34 1.3
219297_at WDR44 NM_019045 … 156 .29 1.2
210904_s_at IL13RA1 U81380 300119 448 .27 1.2
Figure 2. Chromatograms showing the nucleotide changes in
PRPS1. A, c.398ArC transversion in exon 3 in individual III-2 of
family F. B, Segregation of the mutant allele within family F (see
also ﬁg. 1A), as shown by ApoI restriction analysis. C, c.455TrC
transition in exon 4 in individual IV-2 of family N032. D, Segre-
gation of the mutant allele within family N032 (family members
are numbered as in the work of Arts et al.14), as shown by BsmFI
restriction analysis.
P values corrected for multiple testing by use of the
Benjamini-Hochberg method35 were all 1.5, which was
probably the result of using only four hybridizations.
C1GALT1C1 was considered an unlikely candidate gene,
because somatic loss-of-function mutations in this gene
cause Tn syndrome, a rare autoimmune disease in which
subpopulations of blood cells of all lineages carry an in-
completely glycosylatedmembrane glycoprotein.36 The re-
duction in expression of CUL4B and PRPS1 was validated
by qPCR, in which the average expression of the gene of
interest in the cell lines from the two affected individuals
was compared with the average expression in eight sep-
arate cell lines fromdifferent control individuals. In family
members IV-2 and V-5, PRPS1 was reduced in expression
1.3-fold ( ) and 2.4-fold ( ), respectively. Al-Pp .68 Pp .22
though these values are only marginally lower than those
of controls, they were reproducible by qPCR, and they do
conﬁrm the results of the expression array. The expression
of CUL4B in ﬁbroblast cell lines could not be assessed by
qPCR, most likely because of its low expression level in
these cells.
CUL4B and PRPS1 Mutation Analysis
Recently, Tarpey et al.37 reported that mutations in CUL4B
cause an X-linkedmental retardation syndrome associated
with aggressive outbursts, seizures, relative macrocephaly,
central obesity, hypogonadism, pes cavus, and tremor. Al-
though this syndrome appears to be clearly distinct from
Arts syndrome and although we could not conﬁrm the
reduction in expression by qPCR, we nevertheless ana-
lyzed all exons, intron-exon boundaries, and branch sites
of the protein-coding sequence of CUL4B in the two af-
fected members of family N032, IV-2 and V-5. No changes
were identiﬁed (results not shown).
PRPS1 encodes PRS-I, an enzyme that catalyzes the ﬁrst
step in the purine metabolic pathway converting ribose-
5-phosphate to PRPP. Direct DNA sequencing of the seven
exons, intron-exon boundaries, and branch sites in the
two affected family members IV-2 and V-5 revealed one
change, c.455TrC (ﬁg. 2C), that results in the substitution
of a proline for a leucine at position 152 (p.L152P). This
change introduces a BsmFI restriction site. Restriction
analysis by BsmFI digestion showed that this change seg-
regated with the disease in the family (ﬁg. 2D) and was
absent in 301 X chromosomes from healthy Dutch indi-
viduals (data not shown). Subsequent mutation analysis
of PRPS1 in the two affected boys from family F revealed
a second mutation, c.398ArC (ﬁg. 2A), which results in
the substitution of proline for a glutamine at position 133
(p.Q133P). This change removes an ApoI restriction site.
ApoI restriction analysis revealed that this change segre-
gated with the disease in the family (ﬁg. 2B) and was ab-
sent in 308 X chromosomes from healthy Australian in-
dividuals (data not shown).
Molecular Modeling
PRS-I amino acid residues Q133 and L152 are completely
conserved among species, fromhuman to zebraﬁsh (UCSC
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Genome Browser).38 According to the Sorting Intolerant
From Tolerant (SIFT) program,39 which can be used to pre-
dict whether amino acid residues at a speciﬁc position in
a protein can be altered, neither mutation would be tol-
erated at their positions. Models of PRS-I with p.L152P or
p.Q133P were built on the recent crystal structure of hu-
man PRS-I23 (ﬁg. 3). PRS-I is believed to be physiologically
functional as a hexamer, which consists of three homo-
dimers arranged in a propeller-like shape (ﬁg. 3A and 3B).
Q133 is positioned at the interface of the two monomers
of a homodimer and forms a hydrogen bond to D98 from
the other unit in the homodimer (ﬁg. 3A). Thus, the
p.Q133P mutation disrupts two of the intermolecular hy-
drogen bonds between the two monomers (ﬁg. 3C and
3E). As a consequence, both the homodimer and the al-
losteric site would be destabilized. In addition, Q133 and
especially its hydrogen-bonding partner D98 are in close
proximity to the ATP-binding pocket. The neighboring
amino acid residues R96, Q97, K99, and D101 all interact
with the incoming ATP molecule; therefore, the loss of
the hydrogen-bonding partner of D98 could also desta-
bilize the ATP-binding pocket and thus impair PRS-I ac-
tivity. L152 is positioned in the middle of one of the a-
helixes (ﬁg. 3D). Replacement of this leucine with a
proline will break this a-helix conﬁguration (ﬁg. 3F) and,
consequently, will destabilize the protein structure.
PRPP Synthetase Activity in Erythrocytes, Fibroblasts,
and EBV-LCLs
PRPP synthetase activity was measured in erythrocytes
from the two patients, III-2 and III-3; the mother, II-4; the
sister who is not a carrier, III-1; and the father, II-5, from
family F (table 4). There was no activity in erythrocytes
from the affected boys. The activity in their mother, 18
nmol/mg/h, was outside the normal range (24–48 nmol/
mg/h). In both family members without the mutation,
the PRPP synthetase activity was normal. A repeat analysis
of the test gave comparable results.
PRPP synthetase activity was measured in cultured skin
ﬁbroblasts from three affected members of family N032,
IV-2, V-5, and V-27, and from one affected member of
family F, III-2. The PRPP synthetase activity in the patient
ﬁbroblasts was compared with that in ﬁbroblasts from
eight unrelated healthy control individuals. The activity
in the three patients from family N032 was, on average,
13-fold reduced ( , calculated by Student’s t test)P ! .05
compared with the average PRPP synthetase activity in
ﬁbroblasts from controls (table 5). The activity in ﬁbro-
blasts from the patient in family F was equally reduced.
PRPP synthetase activity was also determined in EBV-
LCLs from two carrier females, IV-28 and IV-36, and an
unaffected male, V-10, from family N032. The enzyme
activities in EBV-LCLs from two unrelated healthy control
individuals were analyzed as additional controls. In carrier
females, the PRPP synthetase activity was 486 and 392
nmol/mg/h, which was lower than the activity in the un-
affected male family member, 664 nmol/mg/h, and that
in the two controls, 519 and 636 nmol/mg/h. This re-
duction in PRPP synthetase activity was not statistically
signiﬁcant.
Metabolite Analysis
Serum uric acid levels lower than average were found in
patients and carrier females in family F, with values at the
lower limit of the reference range for age and sex (table
4). Purine urinary proﬁles of the Australian boys were un-
usual, in that hypoxanthine was below the level of de-
tection, whereas xanthine was relatively normal. Urine
uric acid excretion was within the normal range for age.
It should be noted that excreted uric acid, unlike hypo-
xanthine and xanthine, arises from dietary sources as well
as from endogenous metabolism. All other purine and py-
rimidine metabolites appeared to be within the normal
ranges. An unidentiﬁed metabolite with a spectral maxi-
mum at ∼265 nm was noticed in urine from the affected
boys, but its origin was undetermined.
Discussion
In two families with Arts syndrome, we have identiﬁed
two mutations (p.Q133P and p.L152P) in PRPS1. Bothmu-
tations result in a loss of PRS-I activity, as shown both in
silico by molecular modeling and in vitro by PRPP syn-
thetase activity assays in erythrocytes, ﬁbroblasts, and
EBV-LCLs. It is also reﬂected by the undetectable urine
hypoxanthine and reduced plasma uric acid levels in the
two patients from family F. Interestingly, the p.L152Pmu-
tation also seems to cause a small reduction of ∼1.8-fold
in PRPS1 transcript levels, which would be predicted to
cause a reduction in the protein levels in addition to the
reduction in the protein activity. The p.Q133P mutation
did not cause reduced expression levels (data not shown).
Notably, PRPS2 expression levels were not elevated in ﬁ-
broblasts from patients of family N032 (data not shown).
PRPS1 was selected as a candidate gene by a strategy
comprising expression proﬁling. The principle behind this
strategy was to identify small deletions or mutations that
lead to nonsense-mediated RNA decay. It is surprising,
therefore, that a missense mutation was identiﬁed in
PRPS1. It is possible that this missense mutation is directly
responsible for the slightly reduced PRPS1 expression—for
example, by introducing a less favorable codon for the
translation machinery, the disruption of secondary struc-
tures in the mRNA, or feedback/feedforwardmechanisms.
However, we cannot exclude that the mutation is irrele-
vant to the reduced PRPS1 expression levels and that our
selection of the gene was a fortuitous event.
PRPP synthetase enzyme activity is totally absent in
erythrocytes from patients of family F, whereas residual
activity was observed in ﬁbroblasts from one of these pa-
tients. This suggests that the PRS-I activity in erythrocytes
is more severely impaired than that in ﬁbroblasts. The
Figure 3. Three-dimensional model of PRS-I as a hexamer (A and B) and close-ups of the two regions of PRS-I that contain the
mutations p.Q133P (C and E) and p.L152P (D and F). The red spheres indicate the positions of the mutated amino acid residues in the
PRS-I hexamer. The yellow dotted lines represent the hydrogen bonds.
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Table 4. PRPP Synthetase Activity in Erythrocytes and Purine Metabolite Levels in Serum
and Urine from Members of Family F and Two Control Individuals
Individual Sex
Mutation
Carrier
Activitya
(nmol/mg/h)
Serum
Uric Acidb
(mM)
Urinec
(mmol/mol creatine)
Hypoxanthine Xanthine Uric Acid
Family F:
III-1 F No 28 .24 10 [2–55] 8 [5–80] 260 [200–600]
III-2 M Yes 0 .13 !1 [2–55] 8 [5–80] 490 [200–600]
III-3 M Yes 0 .16 !1 [2–55] 10 [5–80] 540 [300–1,000]
II-4 F Yes 18 .16 6 [5–30] 4 [5–30] 320 [200–500]
II-5 M No 40 .37 11 [5–30] 6 [5–30] 250 [200–500]
Control:
1 M No 52 … … … …
2 M No 55 … … … …
a The normal range for PRPP synthetase activity in erythrocytes is 24–48 nmol/mg/h.
b The normal range for serum uric acid levels is 0.12–0.35 mM.
c Age- and sex-dependent normal ranges for the urine metabolites are given in brackets.
Table 5. PRPP Synthetase Activity in
Fibroblasts from Patients and Healthy
Unrelated Control Individuals
Individual Sex
Mutation
Carrier
Activity
(nmol/mg/h)
Family N032:
IV-2 M Yes 1.3
V-5 M Yes 1.1
V-27 M Yes 0
Family F:
III-2 M Yes .4
Control:
1 F No 20.9
2 F No 6.3
3 F No 9.9
4 M No 14.6
5 M No 6.3
6 M No 16.8
7 M No .6
8 M No .3
erythrocyte presents unique challenges to the stability of
its constituent proteins. In addition to being unable to
synthesize new proteins, the erythrocyte is subject to pow-
erful oxidative free radicals. This environment has been
demonstrated to result in loss of function of other en-
zymes containing destabilizing mutations, particularly in
thalassemia.40 The lack of PRS-I activity in erythrocytes
but not in ﬁbroblasts likely reﬂects a reduced stability of
mutant PRS-I protein compared with that of normal PRS-
I. Indeed, a destabilization of PRS-I protein complexes was
predicted by the structural models.
Until now, mutations identiﬁed in PRPS1 were all mis-
sense mutations that cause a superactivity of the protein.
Patients with PRPP synthetase superactivity all have hy-
peruricemia and/or gout.1,41 In contrast to the two novel
loss-of-function missense mutations described here, mo-
lecular modeling showed that the gain-of-function mis-
sense mutations are present in the dimer-trimer interface
(data not shown), which results in impairment of the al-
losteric inhibition of PRS-I by purine nucleotides and free
phosphate.7–10,42 PRPS-related gout is characterized by pu-
rine nucleotide and uric acid overproduction,5–7 gout,6,8 and
sometimes severe neurodevelopmental impairment.8–11
Progressive axonal neuropathy with demyelination has
been described in one family.43 Neurological abnormali-
ties, such as mental retardation, ataxia, hearing impair-
ment, and areﬂexia, that overlap between patients with
Arts syndrome and those with PRPS-related gout (table 2)
indicate that these symptoms are a direct effect of changes
in PRS-I activity.
PRS-I catalyzes the ﬁrst step in the purine metabolic
pathway converting ribose-5-phosphate to PRPP. PRPP is
synthesized solely via PRS-I and/or PRS-II and is essential
for the de novo synthesis of purines and pyrimidines, as
well as for salvage of purines. The mutations in PRPS1 that
we have described here should, consequently, result in
relatively low purine nucleotides in general, which is re-
ﬂected in the reduced serum uric acid levels, although
these levels are subject to diet, and in the low excretion
of urinary hypoxanthine in the two patients of family F.
Although PRPP is also a substrate used in pyrimidine me-
tabolism, pyrimidine nucleotides would not be expected
to be affected as severely as purine nucleotides, because
PRPP is not essential for pyrimidine salvage, as it is for
purine salvage. In addition, dietary pyrimidine nucleo-
sides are able to cross the gut. However, we would predict
that the overall intracellular purine and pyrimidine nu-
cleotide levels in these patients would be lower than nor-
mal, which would mean that Arts syndrome is the ﬁrst
identiﬁed inborn error that affects both purine and py-
rimidine biosynthesis. Indeed, patients with Arts syn-
drome do show symptoms that can be attributed to both
lower purine and lower pyrimidine nucleotide levels. De-
velopmental delay, for instance, is thought to be caused
by a shortage of guanosine triphosphate (GTP) in Lesch-
Nyhan syndrome (MIM 300322).12 Immunodeﬁciency oc-
curs in two purine disorders—namely, adenosine deami-
nase deﬁciency (MIM 102700) and PNP deﬁciency.12 ATP
is critical for the high-energy requirements of bone mar-
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row, and GTP for lymphocyte maturation. Other tissues
with high-energy requirements, such as the brain and ret-
ina, would then also be predicted to be affected. Demy-
elination may be a result of a reduction in pyrimidine
nucleotides, which are essential formembrane andmyelin
synthesis and deposition through their lipid esters (e.g.,
cytidine-5′-phospho [CDP]–choline and CDP-ethanol-
amine).44 Taken together, depletion of both purines and
pyrimidines would give rise to the complex and severe
Arts syndrome phenotype.
Although PRPP synthetases are crucial for de novo pu-
rine synthesis, speciﬁcally ATP can be generated by an
alternative pathway utilizing S-adenosylmethionine
(SAM) as a substrate, as has been demonstrated in human
erythrocytes.45–48 Methyltransferases convert SAM into S-
adenosylhomocysteine that, in turn, is hydrolyzed by S-
adenosylhomocysteine hydrolase, to yield adenosine and
L-homocysteine. This introduces an alternative source of
adenosine that is salvaged through adenosine kinase into
adenosine nucleotides.49 Purine nucleotide recycling can
then convert the SAM-derived adenosine nucleotides into
guanosine nucleotides. Importantly, SAM appears to be
unique among purines in that it can pass across the gut,
where dietary purines are normally oxidized to uric acid.50
Furthermore, SAM also has been shown to pass the blood-
brain barrier. Supplementary SAM has been used safely in
the treatment of depression, neurologic disorders, liver
disease, and osteoarthritis.51 Recently, a patient with
Lesch-Nyhan syndrome was shown to beneﬁt clearly from
SAM administration, without untoward side effects.52 This
suggests that low GTP levels can also be elevated by SAM.
One of us (J.A.D.) hypothesizes that supplementary SAM
in the diet of our PRS-I–deﬁcient patients could perhaps
alleviate the clinical symptoms caused by a shortage of
speciﬁcally adenosine-derived nucleotides. In addition,
SAM is also a source ofmethionine, which couldovercome
a possible deﬁciency of methylation processes caused by
low ATP levels and thus low endogenous SAM levels, be-
cause SAM synthesis is ATP dependent. By relieving the
stress on purine nucleotides, it is possible theoretically to
reduce the effects of pyrimidine nucleotide depletion. Di-
etary pyrimidines, unlike purines, are absorbed into the
body and then salvaged as nucleosides, principally from
uridine.53 We have begun dietary supplementation with
SAM in the Australian patients and may consider uridine
supplementation if indicated, although we predict that
dietary uridine may be sufﬁcient.
In summary, PRS-I loss-of-function mutations cause
Arts syndrome. The clinical presentation is reminiscent of
symptoms seen in other purine and pyrimidine disorders.
We propose that these symptoms are the result of nucle-
otide depletion in key energy-requiring tissues. A deﬁ-
ciency in purine nucleotides could theoretically be com-
pensated partially by supplementary SAM, and a trial of
SAM is currently under way in the two affected Australian
males.
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